Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Alexandria Real Estate Equities, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Alexandria Real Estate Equities securities between January 27, 2025, and October 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 26, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that defendants provided misleading information regarding Alexandria Real Estate's expected revenue and funds from operations growth for the 2025 fiscal year, particularly concerning its Long Island City property [5]. - Defendants reportedly made positive statements about the leasing value of the LIC property while concealing adverse facts, leading to investor damages when the truth was revealed [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jayud Global Logistics Ltd. during the specified Class Period of the upcoming lead plaintiff deadline on January 20, 2026 [1] Group 1: Class Action Details - Investors who purchased Jayud securities between April 21, 2023, and April 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm or visiting their website [3][6] - The lead plaintiff must file a motion with the Court by January 20, 2026, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at that time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Jayud made materially false and misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [5] - Specific allegations include the use of social media misinformation, offshore accounts for share dumping, and omission of risks related to false rumors and artificial trading activity [5]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors in Sprouts Farmers Market, Inc. for the period between June 4, 2025, and October 29, 2025, due to alleged misleading statements regarding the company's growth potential [2][6]. Group 1: Class Action Details - The class action is aimed at purchasers of Sprouts Farmers Market securities and sellers of put options during the specified Class Period [2][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A lead plaintiff must file a motion with the court by January 26, 2026, to represent other class members [4]. Group 2: Allegations Against the Company - The lawsuit claims that the defendants provided overly positive statements about Sprouts Farmers Market's growth potential while concealing material adverse facts [6]. - It is alleged that the company misled investors by asserting that a cautious consumer base would benefit the company, despite evidence suggesting a potential slowdown in sales growth [6]. - The lawsuit contends that when the true state of the company's growth potential was revealed, investors suffered damages [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized as a leader in the field, being ranked No. 1 for securities class action settlements in 2017 and consistently in the top 4 since 2013 [5]. - The founding partner has received accolades, including being named a Titan of Plaintiffs' Bar by Law360 in 2020 [5].

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYEDecember 05, 2025 5:34 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Per ...

Core Viewpoint - Rosen Law Firm is urging investors of Perrigo Company plc to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period from February 27, 2023, to November 4, 2025 [1]. Group 1: Legal Action Details - Investors who purchased Perrigo securities during the class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from significant underinvestment and required substantial capital expenditures [5]. - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo about its business operations were materially misleading and lacked a reasonable basis, resulting in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of $0.69 per share, compared to a net loss of $0.15 per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart's stock experienced a decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Insights - IDEAYA Biosciences has received FDA clearance for an IND application to initiate a Phase 1 clinical trial for IDE034, a bispecific B7H3/PTK7 TOP1 antibody-drug conjugate, expected to start patient enrollment in Q1 2026 [1][2] - The drug targets solid tumors expressing B7H3 and PTK7, with co-expression rates in lung, colorectal, and head and neck cancers reported at approximately 30%, 46%, and 27% respectively [1][5] - IDE034 has shown strong anti-tumor activity in preclinical studies, supporting its advancement into clinical development [3][5] Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, aiming to develop targeted therapies that are aligned with the genetic drivers of cancer [4] - The company has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications [4] Clinical Development Strategy - The company is advancing a differentiated clinical strategy with three potentially first-in-class clinical-stage programs aimed at enhancing the efficacy of TOP1 ADCs through a PARG DDR combination mechanism [2][3] - Preclinical studies suggest that combining IDE034 with IDE161, a PARG inhibitor, may enhance anti-tumor activity in patients with solid tumors co-expressing B7H3 and PTK7 [3][5]

Core Viewpoint - Rosen Law Firm is urging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1 - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 16, 2026 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [5]. Group 2 - The lawsuit claims that Skye Bioscience made materially false and misleading statements regarding its product nimacimab, including its effectiveness and commercial prospects, which led to investor damages when the truth was revealed [6]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Firefly Aerospace securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to seek recovery of investor losses [2]. - The investigation follows a report from The Wall Street Journal indicating that Firefly Aerospace posted a wider loss and lower revenue in its latest quarter, which was the company's first earnings report since its stock market debut [3]. Group 2: Company Performance - Firefly Aerospace's stock experienced a significant decline of 15.3% on September 23, 2025, following the negative earnings report [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has received recognition for its attorneys from Lawdragon and Super Lawyers [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Stride securities between October 22, 2024, and October 28, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Stride made misleading statements regarding its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits, which led to damages for investors when the truth was revealed [5].